Comparison of Actinic Keratosis and Severity Index with Physician Global Assessment and Total Lesion Count and the Ability to Predict Skin Cancer

Comparison of Actinic Keratosis and Severity Index with Physician Global Assessment and Total Lesion Count and the Ability to Predict Skin Cancer

Authors

  • Ayda Acar Ege University, Medical Faculty, Department of Dermatology and Venereology, Izmir, Turkey
  • Isil Karaarslan Ege University, Medical Faculty, Department of Dermatology and Venereology, Izmir, Turkey

Keywords:

actinic keratosis, AKASI, physician global assessment, skin cancer, total lesion count

Abstract

Introduction: Actinic keratosis (AK) is a known indicator for sun damage, and subsequent squamous cell cancer may develop. The actinic keratosis and severity index (AKASI) is a recently developed tool that can evaluate both field cancerization and AK severity.

Objectives: We sought to evaluate if AKASI was a good predictor of cancer in AK patients and to compare AKASI with both the Physician Global Assessment (PGA) and total lesion count (TLC).

Methods:  Ninety patients with AK were included in the study. Each patient was examined, and AKs were scored with AKASI, PGA and TLC by 2 dermatologists. The AKASI, PGA and TLC values were compared between patients with skin cancer and patients without skin cancer.

Results: Mean AKASI, PGA, and TLC scores were 4.9, 1.7 and 9 respectively. The patients with skin cancer had higher scores of AKASI, PGA and TLC compared to the patients without skin cancer (P = 0.022, P = 0.014, P = 0.005, respectively). AKASI, PGA and TLC were very strongly correlated with each other (P < 0.001). The AKASI threshold value for NMSC was determined to be 5.1.

Conclusions: AKASI, PGA and TLC may be used in the assessment of the severity of AK in daily practice or studies and may be considered as valuable tools in determining high-risk patients and to choose treatment option. AKASI seems to have an advantage to give a numeric threshold value for skin cancer.

References

Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2017;177(2):350-358. DOI: 10.1111/bjd.14852. PMID: 27500794.

Soyer PH, Rigel DS, McMeniman E. Actinic keratosis, basal cell carcinoma and squamous cell carcinoma. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. Fourth edition. Elsevier, 2018:1872-1893.

de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176(1):20-43. DOI: 10.1111/bjd.15107. PMID: 28098380.

Dirschka T, Gupta G, Micali G, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017;28(5):431-442. DOI: 10.1080/09546634.2016.1254328. PMID: 27796187.

Corchado-Cobos R, García-Sancha N, González-Sarmiento R, Pérez-Losada J, Cañueto J. Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci. 2020,22;21(8):2956. DOI: 10.3390/ijms21082956. PMID: 32331425. PMCID: PMC7216042.

Richard MA, Amici JM, Basset-Seguin N, Claudel JP, Cribier B, Dreno B. Management of actinic keratosis at specific body sites in patients at high risk of carcinoma lesions: expert consensus from the AKTeam™ of expert clinicians. J Eur Acad Dermatol Venereol. 2018;32(3):339-346. DOI: 10.1111/jdv.14753. PMID: 29235161.

Williams VL, Cohen PR, Stewart DJ. Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol. 201;50(4):396-402. DOI: 10.1111/j.1365-4632.2010.04822.x. PMID: 21413947.

Gandini S, Palli D, Spadola G, et al. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2018;122:1-9. DOI: 10.1016/j.critrevonc.2017.12.003. Epub 2017 Dec 13. PMID: 29458778.

National Comprehensive Cancer Center. NCCN clinical practice guidelines in oncology; squamous cell carcinoma (V1.2020). Available from www.nccn.org. Accessed November 25, 2020.

Schmitz L, von Dobbeler C, Gupta G, et al. Photodynamic therapy leads to significant improvement of actinic keratosis area and severity index (AKASI). Photodiagnosis Photodyn Ther. 2018; 21:66-70. DOI: 10.1016/j.pdpdt.2017.10.007. PMID: 29051122.

Heppt MV, Leiter U, Steeb T, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges. 2020;18(3):275-294. DOI: 10.1111/ddg.14048. PMID: 32130773.

Dirschka T, Pellacani G, Micali G, et al. Athens AK Study Group. A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J Eur Acad Dermatol Venereol. 2017;31(8):1295-1302. DOI: 10.1111/jdv.14267. PMID: 28401585.

Pellacani G, Gupta G, Micali G, et al. Actinic Keratosis Area Severity Index (AKASI): reproducibility study and comparison with total lesion count. Br J Dermatol. 2018;179(3):763-764. DOI: 10.1111/bjd.16559. PMID: 29572818.

Schmitz L, Gambichler T, Gupta G, Stücker M, Dirschka T. Actinic keratosis area and severity index (AKASI) is associated with the incidence of squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2018;32(5):752-756. DOI: 10.1111/jdv.14682. PMID: 29117441.

Benati E, Longhitano S, Pampena R, et al. Digital follow-up by means of dermatoscopy and reflectance confocal microscopy of actinic keratosis treated with Imiquimod 3.75% cream. J Eur Acad Dermatol Venereol. 2020;34(7):1471-1477. DOI: 10.1111/jdv.16143.. PMID: 31838781.

Schmitz L, Gupta G, Segert MH, et al. Diclofenac sodium 3% in hyaluronic acid 2.5% gel significantly diminishes the Actinic Keratosis Area and Severity Index. Skin Pharmacol Physiol. 2018;31(4):206-211. DOI: 10.1159/000488248. PMID: 29791916.

Jordan M, Ghoreschi K, Eberle FC. Daylight photodynamic therapy for severe facial and scalp actinic keratosis: a prospective non-sponsored single-centre study employing the actinic keratosis area and severity index (AKASI). Eur J Dermatol. 2019;29(1):67-74. DOI: 10.1684/ejd.2018.3492. PMID: 30827943.

von Dobbeler C, Schmitz L, Dicke K, Szeimies RM, Dirschka T. PDT with PPIX absorption peaks adjusted wavelengths: Safety and efficacy of a new irradiation procedure for actinic keratoses on the head. Photodiagnosis Photodyn Ther. 2019;27:198-202. DOI: 10.1016/j.pdpdt.2019.05.015. PMID: 31176762.

Dréno B, Cerio R, Dirschka T, et al. A novel actinic keratosis field assessment scale for grading actinic keratosis disease severity. Acta Derm Venereol. 2017;97(9):1108-1113. DOI: 10.2340/00015555-2710. PMID: 28536731.

Downloads

Published

2022-02-02

Issue

Section

Original Article

How to Cite

1.
Comparison of Actinic Keratosis and Severity Index with Physician Global Assessment and Total Lesion Count and the Ability to Predict Skin Cancer . Dermatol Pract Concept [Internet]. 2022 Feb. 2 [cited 2024 Apr. 23];12(1):e2022031. Available from: https://dpcj.org/index.php/dpc/article/view/1838

Share